Morphic Holding Inc

Morphic Holding, Inc. operates as a biopharmaceutical company, which engages in the research and development of oral small-molecule integrin therapeutics. It operates a Morphic integrin technology platform, MInT platform, to create a broad pipeline of programs across a variety of therapeutic areas. The company was founded by Timothy A. Springer in August 2014 and is headquartered in Waltham, MA.

Earnings data Q4 2020

Earnings data Q1 2021

Earnings data Q2 2021

Earnings data Q3 2021

Earnings data Q4 2021

Earnings data Q1 2022

Earnings data Q2 2022

Earnings data Q3 2022

Earnings data Q4 2022

Earnings data Q1 2023

Earnings data Q2 2023

Earnings data Q3 2023

Earnings data Q4 2023

Earnings data Q1 2024

Earnings data Q2 2024

Earnings data Q3 2024

Revenue

Cost of revenue

Gross profit

Operating expenses

SG&A

Other

Operating income

EBITDA

Net income

Earnings per share

Total assets

Current assets

Cash & equivalents

Receivables

Inventory

Non-current assets

Net PPE

Intangibles

Total liabilities

Current liabilities

Short term debt

Income tax payable

Non-current liabilities

Long-term debt

Total equity

Stockholders equity

Minority interest

Total liabilities & equity

Total debt

Net debt

Book value per share

Cash from operations

Funds from operations

Change in working capital

Cash from investing

Capital expenditure

Purchase/sale of investments

Purchase/sale of business

Other sources

Cash from financing

Change in stock

Change in debt

Cash dividends paid

Cash from other sources

Net change in cash

Free cash flow

Morphic Holding, Inc., operates as a biopharmaceutical company, which researches and develops oral small-molecule integrin therapeutics. It operates a Morphic integrin technology platform, MInT platform, to create a broad pipeline of programs across a variety of therapeutic areas. The company was founded by Timothy A. Springer in August 2014 and is headquartered in Waltham, MA.

Morphic Holding: Potentially The Next Prometheus Biosciences

Agios Pharmaceuticals

Amylyx Pharmaceuticals

Xencor

Harmony Biosciences Holdings

Kymera Therapeutics

 Pliant Therapeutics

Generally speaking, biotech stocks to buy offer investors an excellent opportunity for significant upside success. According to Grand View Research, the global market size for the industry reached $1.02 trillion in 2021.

7 Biotech Stocks to Buy for 100% Returns

WALTHAM, Mass., March 03, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that its management team will participate a panel discussion focused on new approached to treat gastroenterological diseases and a corporate fireside chat at the TD Cowen 43rd Annual Health Care Conference.

Morphic to Present at TD Cowen 43rd Annual Health Care Conference

-Initiated and completed enrollment for EMERALD-1 phase 2a trial of MORF-057 in ulcerative colitis; topline data expected 2Q23-

Morphic Announces Corporate Highlights and Financial Results for the Full Year 2022

WALTHAM, Mass., Feb. 14, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that its management team will participate in the virtual SVB Leerink Global Healthcare conference including a hosted fireside chat.

Morphic to Present at SVB Leerink Global Healthcare Conference

Morphic Holding has curled up off recent lows and caught a strong bid into the new year. It broke out above its longer-term resistance level and has finished above this mark for the last 3-weeks of trade.

Morphic Holding: Technical Case For Tactical Medium-Term Buy (Technical Analysis)

Morphic Holding, Inc. (MORF) was a big mover last session on higher-than-average trading volume. The latest trend in earnings estimate revisions might not help the stock continue moving higher in the near term.

Morphic Holding, Inc. (MORF) Surges 18.7%: Is This an Indication of Further Gains?

WALTHAM, Mass., Jan. 05, 2023 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biotechnology company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Praveen Tipirneni, M.D., President and Chief Executive Officer, will present at the 41st Annual J.P. Morgan Healthcare Conference on Wednesday, January 11, 2023 at 2:15 PM PST.

Morphic to Present at the 41st Annual J.P. Morgan Healthcare Conference

WALTHAM, Mass., Nov. 09, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Dr. Bruce Rogers, President of Morphic, will participate in a fireside chat at the Jefferies London Healthcare Conference on Wednesday, November 16th, at 10:55 AM GMT.

Morphic Announces Participation in 2022 Jefferies London Healthcare Conference

Morphic Holding, Inc. (MORF) delivered earnings and revenue surprises of 2.50% and 46.39%, respectively, for the quarter ended September 2022. Do the numbers hold clues to what lies ahead for the stock?

Morphic Holding, Inc. (MORF) Reports Q3 Loss, Lags Revenue Estimates

Completed enrollment of EMERALD-1 phase 2a trial of MORF-057 in patients with ulcerative colitis ahead of schedule

Morphic Announces Corporate Highlights and Financial Results for the Third Quarter 2022

Saturating receptor occupancy at 100 and 200 mg BID doses

Morphic Presents New Positive MORF-057 Phase 1 Data at American College of Gastroenterology Annual Meeting 2022

Phase 2a trial of MORF-057 in patients with ulcerative colitis will extend enrollment to allow patients currently screened to enter study if eligible Phase 2a trial of MORF-057 in patients with ulcerative colitis will extend enrollment to allow patients currently screened to enter study if eligible

Morphic Announces Complete Enrollment of EMERALD-1 Main Cohort Ahead of Projections

200 mg BID dose demonstrates receptor saturation and statistically significant increases in key circulating T lymphocyte populations

Morphic Presents New Positive MORF-057 Phase 1 Data at UEG Week 2022

Morphic Holding, Inc. (MORF) Moves 7.3% Higher: Will This Strength Last?

Recognized for pioneering work in field of integrin receptor biology, leading to new treatments for multiple autoimmune disorders

Morphic Congratulates Timothy A. Springer, PhD as 2022 Albert Lasker Basic Medical Research Award Honoree

Paper describes key insight into integrin conformation, overcoming critical drug development challenge

Morphic Celebrates Foundational Integrin Research Published in Cell

The average of price targets set by Wall Street analysts indicates a potential upside of 107.9% in Morphic Holding, Inc. (MORF). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Wall Street Analysts Predict a 108% Upside in Morphic Holding, Inc. (MORF): Here's What You Should Know

The average of price targets set by Wall Street analysts indicates a potential upside of 96.7% in Morphic Holding, Inc. (MORF). While the effectiveness of this highly sought-after metric is questionable, the positive trend in earnings estimate revisions might translate into an upside in the stock.

Can Morphic Holding, Inc. (MORF) Climb 97% to Reach the Level Wall Street Analysts Expect?

Morphic Holding, Inc. (MORF) delivered earnings and revenue surprises of 183.95% and 1,317.32%, respectively, for the quarter ended June 2022. Do the numbers hold clues to what lies ahead for the stock?

Morphic Holding, Inc. (MORF) Surpasses Q2 Earnings and Revenue Estimates

Continued enrollment of EMERALD-1 phase 2a trial of MORF-057 in patients with ulcerative colitis

Morphic Announces Corporate Highlights and Financial Results for the Second Quarter 2022

Morphic Holding, Inc. (MORF) possesses the right combination of the two key ingredients for a likely earnings beat in its upcoming report. Get prepared with the key expectations.

Morphic Holding, Inc. (MORF) Expected to Beat Earnings Estimates: Can the Stock Move Higher?

WALTHAM, Mass., June 09, 2022 (GLOBE NEWSWIRE) -- Morphic Therapeutic (Nasdaq: MORF), a biopharmaceutical company developing a new generation of oral integrin therapies for the treatment of serious chronic diseases, today announced that Bruce Rogers, Ph.D., President of Morphic, will give a corporate presentation at the Jefferies Global Healthcare Conference on Thursday, June 9th at 2:00 PM ET.

Morphic to Present at 2022 Jefferies Global Healthcare Conference

Experienced Regulatory Leader with Record of Global and Regulatory Success Across Multiple Therapeutic Areas Experienced Regulatory Leader with Record of Global and Regulatory Success Across Multiple Therapeutic Areas

Morphic Appoints Joanne Gibbons as Senior Vice President of Regulatory Affairs

Morphic Holding, Inc. (MORF) delivered earnings and revenue surprises of -19.72% and 52.36%, respectively, for the quarter ended March 2022. Do the numbers hold clues to what lies ahead for the stock?

News for Morphic Holding Inc Stock (MORF)